Dongcheng Pharmaceutical announced that its holding subsidiary Yantai Lannacheng Biotechnology Co., Ltd. has received an approval notice for the clinical trial of the 177 Lu-LNC1010 injectable drug approved by the State Drug Administration and will conduct clinical trials in the near future. This drug is a radiotherapy drug targeting somatostatin receptor 2 and is suitable for treating gastroenteropancreatic neuroendocrine tumors positive for somatostatin receptor 2. Currently, only Novartis's same-target drug Lutathera is on the market in the world, with sales of US$605 million in 2023. Projects related to 177 Lu-LNC1010 injections have invested a total of about 12.822,700 yuan in R&D expenses. The drug has a long cycle from development to marketing, and there is uncertainty. The company will actively promote R&D projects and disclose progress in a timely manner.
东诚药业：控股子公司获药物临床试验批准
Dongcheng Pharmaceutical: Holding subsidiary approved for drug clinical trials
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.